Amino Nitrogen Attached To Aryl Ring Or Aryl Ring System By An Acyclic Carbon Or Acyclic Chain Patents (Class 514/649)
  • Patent number: 10987370
    Abstract: Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: April 27, 2021
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Rina Rosin-Arbesfeld, Michal Caspi, Dalia Megiddo
  • Patent number: 10919841
    Abstract: The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: February 16, 2021
    Assignee: Research Triangle Institute
    Inventors: Frank Ivy Carroll, Bruce Edward Blough, Philip Abraham
  • Patent number: 10806710
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 20, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10787421
    Abstract: The invention provides compounds formula (I) and salts thereof: wherein R1-R4 have any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia. The compounds are also useful to lower IL-4, IL-5, or IL-15 levels in an animal.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: September 29, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Carl Wagner, Peter Jurutka, Pamela Marshall
  • Patent number: 10758500
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 1, 2020
    Assignee: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: Mitchell Steiner, Harry Fisch
  • Patent number: 10710957
    Abstract: Motuporamine agents having antimicrobial activity and uses thereof.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 14, 2020
    Assignees: University of Central Florida Research Foundation, Inc., Inserm Transfert, S.A.
    Inventors: Otto Phanstiel, IV, Jean-Michel Brunel
  • Patent number: 10596261
    Abstract: The present invention provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises vinyl lactam derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared by a continuous process and has a Brookfield cohesion of less than 0.12 kPa, a bulk density of at least 0.249 gram/milliliter and a flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 24, 2020
    Inventors: Divya Tewari, Yevgeniya A. Titova, Brad Beissner, Thomas Durig
  • Patent number: 10588914
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: March 17, 2020
    Assignee: ENCORE DERMATOLOGY, INC.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 10568851
    Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: February 25, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Krzysztof Palczewski, Yu Chen
  • Patent number: 10543174
    Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: January 28, 2020
    Assignee: Synthon B.V.
    Inventors: Agnes Fernandez Pena, Jose Velada Calzada, Rohit Kumar, Lisardo Alvarez Fernandez
  • Patent number: 10485767
    Abstract: Described herein, inter alia, are compositions, formulations, methods, and systems for reducing regional fat deposits and treating fat-related conditions.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: November 26, 2019
    Inventor: John Daniel Dobak, III
  • Patent number: 10463635
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: November 5, 2019
    Assignee: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: Mitchell Steiner, Harry Fisch
  • Patent number: 10369144
    Abstract: The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. The central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 6, 2019
    Assignee: PureTech Health LLC
    Inventors: Eric Elenko, Philip E. Murray, III, Andrew C. Miller
  • Patent number: 10258598
    Abstract: The invention relates to the field of prevention and treatment of cancer, in particular suppression of tumor manifestation. The invention also relates to compounds for use in this field. A novel tumor manifestation suppression (TMS) regulation in a mammalian brain is recognized. The invention relates to compounds, pharmaceutical preparations, in particular medicaments for use in the prevention and treatment of cancer, in particular suppression of tumor manifestation based on said TMS regulation as well as methods for the same.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: April 16, 2019
    Assignees: Semmelweis University, Fujimoto Co. Ltd.
    Inventors: József Knoll, Ildikó Miklya, Péter Ferdinandy, Dezso Schuler, Zsuzsanna Schaff, Sándor Eckhardt
  • Patent number: 10238643
    Abstract: Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 26, 2019
    Assignee: PureTech Health LLC
    Inventors: Eric Elenko, Philip E. Murray, III, Andrew C. Miller
  • Patent number: 10207982
    Abstract: The present invention refers to new amorphous and crystalline solid forms of desvenlafaxine, also known as O-desmethylvenlafaxine or desmethylvenlafaxine, and to its salts, solvates, hydrates and polymorphs thereof, as well as to their use in the manufacture of a pharmaceutical composition useful in the treatment of depression and/or as a selective serotonin and norepinephrine reuptake inhibitor and also in menopause-associated vasomotor disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: February 19, 2019
    Assignee: Alparis, S.A. DE C.V.
    Inventors: Jorge Guillermo Domínguez Chávez, Karina Mondragón Vásquez, Hugo Morales Rojas, Dea Herrera Ruiz, Herbert Höpfl, Reyna Reyes Martínez, Javier Hernández Illescas, Juan Pablo Senosiain Peláez
  • Patent number: 10179137
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: January 15, 2019
    Assignee: PROMIUS PHARMA LLC
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 10166248
    Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one ?-KA scavenger compound, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: January 1, 2019
    Assignee: Vanderbilt University
    Inventors: John A. Oates, Olivier Boutaud, Irene Zagol-Ikapitte
  • Patent number: 10105375
    Abstract: Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 23, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum
  • Patent number: 10074170
    Abstract: A method of producing a tablet in which an uncoated tablet is coated by a coating agent, the method including: a coating process of coating uncoated tablets with a coating agent by spray coating the coating agent onto tablets that are churned and tumbled inside a container, and drying the tablets inside the container by supplying drying air into the container and exhausting air from the container, wherein spray coating conditions, including air supply temperature, air supply rate, and spray speed, are controlled according to the weight of the coating agent with which the uncoated tablets are coated, such that the humidity of air exhausted during spray coating is within a range of from 14% RH to 30% RH.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: September 11, 2018
    Assignees: FUJI XEROX CO., LTD., Daiichi Sankyo Company, Limited
    Inventors: Kensuke Ito, Yasuhiro Suzuki
  • Patent number: 10064875
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: September 4, 2018
    Assignee: PROMIUS PHARMA LLC
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9987492
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: June 5, 2018
    Assignee: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Kevin J. Tracey, Jared M. Huston
  • Patent number: 9962372
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of benzydamine and an antimycotic active ingredient, said combination having a synergistic effect in the treatment of mycosis.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: May 8, 2018
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Claudio Milanese, Alessandra Capezzone De Joannon, Serena Tongiani, Luca Donati
  • Patent number: 9956231
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 1, 2018
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9913847
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: March 13, 2018
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 9895360
    Abstract: Combination compositions and kits comprising an analgesic and an antihistamine are provided as well as methods of use in treating sunburn.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: February 20, 2018
    Assignee: Sephoris Pharmaceuticals, LLC
    Inventors: Talal Sheena, Melwyn Abreo
  • Patent number: 9877974
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: January 30, 2018
    Assignee: Dr. Reddy's Laboratories, Ltd.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9844520
    Abstract: Described herein, inter alia, are compositions, formulations, methods, and systems for reducing regional fat deposits and treating fat-related conditions.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: December 19, 2017
    Inventor: John Daniel Dobak, III
  • Patent number: 9782483
    Abstract: The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: October 10, 2017
    Assignee: Laboratories Del Dr. Esteve, S.A.
    Inventors: José Miguel Vela Hernández, Xavier Codony-Soler, Daniel Zamanillo-Castanedo
  • Patent number: 9775851
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 3, 2017
    Assignee: Dr. Reddy's Laboratories, Ltd.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9763955
    Abstract: Disclosed in certain embodiments is a method of decreasing gastric emptying comprising administering to a subject an effective amount of a sodium-channel blocker to decrease gastric emptying.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: September 19, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside, Nathan Lautermilch
  • Patent number: 9732031
    Abstract: The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 15, 2017
    Assignee: DeuteRx, LLC
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H. T. van der Ploeg
  • Patent number: 9696306
    Abstract: Successful CNS drug discovery requires a scalable, highly physiological neuronal model. Using directed differentiation of mouse embryonic stem (mES) cells, including mES cells isolated from a mouse model of Alzheimer's disease (AD), a highly homogeneous primary neuronal model amenable to phenotypic assays for production and synaptotoxicity of amyloid ?-peptide was developed. This model furnishes a highly physiological and AD-relevant platform suitable for high throughput small molecule and functional genetic screens, providing specific small molecule compounds identified by such screens.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: July 4, 2017
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Tae-Wan Kim, Laura Beth Johnson McIntire, Natalie Landman, Gina Finan
  • Patent number: 9662320
    Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: May 30, 2017
    Assignee: Universitat Pompeu Fabra
    Inventors: Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez
  • Patent number: 9655907
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: May 23, 2017
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9642911
    Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: May 9, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Patent number: 9629834
    Abstract: Provided is a pharmaceutical composition which enables the inhibition of formation and/or enlargement of cerebral aneurysm or the regression of cerebral aneurysm. The pharmaceutical composition for the inhibition of formation and/or enlargement of cerebral aneurysm or for the regression of cerebral aneurysm of the present invention, which includes a S1P1 receptor agonist as an active ingredient, enables the inhibition of formation and/or enlargement of cerebral aneurysm or the regression of cerebral aneurysm, and enables the prevention and/or treatment of a disease associated with cerebral aneurysm.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: April 25, 2017
    Assignees: KYOTO UNIVERSITY, ASTELLAS PHARMA INC.
    Inventors: Tomohiro Aoki, Ichiro Aramori, Jun Hirose, Rie Yamamoto
  • Patent number: 9533996
    Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: January 3, 2017
    Assignee: Dart Neuroscience (Cayman) Ltd.
    Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael Weinhouse
  • Patent number: 9439911
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: September 13, 2016
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9433630
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: September 6, 2016
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9433589
    Abstract: The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising adrenaline and citric acid showing improved storage stability.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: September 6, 2016
    Assignee: Rigshospitalet
    Inventors: Philip Hansen, Pär Johansson, Jens Kindtler
  • Patent number: 9375405
    Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: June 28, 2016
    Assignee: Amgen, Inc.
    Inventors: Glen Gary Lawrence, Francisco J. Alvarez, Hung-Ren H. Lin, Tzuchi R. Ju
  • Patent number: 9364485
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: June 14, 2016
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9314449
    Abstract: The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.
    Type: Grant
    Filed: December 24, 2012
    Date of Patent: April 19, 2016
    Assignee: HOSPIRA, INC.
    Inventors: Marcelo Garcia da Rocha, Wayne Wisemandle, Dennis Stalker, Edward Koo
  • Patent number: 9192599
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: November 24, 2015
    Assignee: Onxeo S.A.
    Inventors: Pierre Attali, Caroline Lemarchand, Vanessa Roulet, Claire Scheuir, Lorraine Zakin
  • Patent number: 9034927
    Abstract: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, reduce biofilms, and/or inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: May 19, 2015
    Assignees: CURZA GLOBAL, LLC, UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Dustin Williams, Ryan Looper, Sujeevini Jeyapalina, Travis Haussener, Paul R. Sebahar, Hari Kanna Reddy
  • Publication number: 20150133407
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 14, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150126511
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 7, 2015
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Larry R. BUSH, Jianguo MA, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, John E. CAMPBELL
  • Patent number: 8993807
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: March 31, 2015
    Assignee: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Patent number: 8993571
    Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: March 31, 2015
    Assignee: Galderma Laboratories, L.P.
    Inventors: Jack A. DeJovin, Isabelle Jean DeJovin